SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-061558
Filing Date
2023-11-09
Accepted
2023-11-09 08:16:03
Documents
16
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cadl-20231109.htm   iXBRL 8-K 53946
2 EX-99.1 cadl-ex99_1.htm EX-99.1 65273
3 GRAPHIC img160460863_0.jpg GRAPHIC 26606
4 GRAPHIC img160460863_1.jpg GRAPHIC 70057
5 GRAPHIC img160460863_2.jpg GRAPHIC 26680
  Complete submission text file 0000950170-23-061558.txt   422235

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cadl-20231109_lab.xml EX-101.LAB 14719
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cadl-20231109.xsd EX-101.SCH 2464
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cadl-20231109_pre.xml EX-101.PRE 11445
10 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20231109_htm.xml XML 4884
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 231390186
SIC: 2836 Biological Products, (No Diagnostic Substances)